ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF) Sellers Strengthened By 3.05% Their Shorts As Of May 16, 2018

May 16, 2018 - By Joseph Norton

ARGENX SE (OTCMKTS:ARGNF) Corporate Logo

ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF) had an increase of its shorted shares by 3.05%. FINRA issued shorted shares of ARGNF’s total 20,300 shares. The 19,700 previous shares are up with 3.05%. With Average volume 100, ARGNF’s previous position will take 203 days to recover. ARGEN X NV ORDINARY SHARES NETHERLANDS float short is 0.09%.

$85 was the last price.Since May 16, 2017 it’s 0.00% up thus . ARGNF underperformed by 11.55% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer.The company has $ market cap. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.Currently it has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: